MedNet to Unveil Multiple iMedNet EDC Delivery Options at the 2014 DIA Annual Meeting
MedNet will be showcasing iMedNet EDC, its flagship eClinical solution, at the 2014 Drug Information Association Annual Meeting.
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, will be showcasing iMedNet EDC, its flagship eClinical solution, at the 2014 Drug Information Association (DIA) Annual Meeting, June 16-18 in San Diego, California. iMedNet EDC provides a flexible, intuitive and affordable eClinical platform that effectively supports research initiatives of any size, phase or duration, in any therapeutic area, anywhere in the world.
MedNet is pleased to offer three iMedNet EDC delivery programs, each designed to support the unique needs and requirements of our customers:
- iMedNet iBuild Program – Developed for pharma, biotech, IVD and medical device companies wishing to efficiently build their own studies in-house. Includes comprehensive iMedNet Designer training and support services to ensure the success of each research initiative.
- iMedNet Partner Program – Created specifically for CROs and healthcare consultants looking for a fast, easy-to-use and cost-effective do-it-yourself eClinical solution. Includes complete sales and marketing support, iMedNet Advisory Forum membership and special pricing discounts.
- iMedNet Access Program – Ideal for any organization wanting to outsource their iMedNet study configurations for any reason. MedNet’s Professional Technology Services Team provides turnkey setup and deployment services, from system build and testing to end-user support.
DIA attendees are encouraged to stop by MedNet’s booth #924 in the exhibits area for more information and to see iMedNet EDC in action. You may also contact MedNet at any time to schedule a free, no-obligation demonstration.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
